Health
Research And Development
Medical

Achillion Pharmaceuticals

$2.93
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.20 (-6.39%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell ACHN and other stocks, options, ETFs, and crypto commission-free!

About

Achillion Pharmaceuticals, Inc. engages in the discovery and development of small molecule drug therapies for immune system disorders. It offers its propriety platform of potent and specific complement factor D inhibitors for AP-mediated diseases. Read More The company was founded on August 17, 1998 and is headquartered in New Haven, CT.

Employees
56
Headquarters
Blue Bell, Pennsylvania
Founded
1998
Market Cap
406.44M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
1.62M
High Today
$3.16
Low Today
$2.93
Open Price
$3.12
Volume
695.61K
52 Week High
$3.99
52 Week Low
$1.29

Collections

Health
Research And Development
Medical
Biotechnology
Pharmaceutical
Therapy
Technology
US

News

Seeking AlphaMar 14

Achillion Pharmaceuticals (ACHN) Presents At Barclays Global Healthcare Conference - Slideshow

The following slide deck was published by Achillion Pharmaceuticals, Inc. in conjunction with this event. 1 24 Click to enlarge Notes:...

143
Yahoo FinanceMar 8

Achillion (ACHN) Reports Narrower-Than-Expected Loss in Q4

Achillion Pharmaceuticals, Inc. ACHN incurred a loss of 12 cents per share in the fourth quarter of 2018, narrower than the Zacks Consensus Estimate of a loss of 15 cents and the year-ago loss of 17 cents. The company did not generate any revenues in the reported quarter in absence of an approved product in its portfolio. Shares of Achillion have soared 67.3% so far this year, outperforming the industry’s increase of 11.1%. Quarter in Detail Research and development (R&D) expenses decreased nearly 20.8%...

99
Markets InsiderMar 7

Achillion Reports Fourth Quarter and Full Year 2018 Financial Results

- Phase 2 trial enrollment on schedule in PNH combo, interim data expected in Q2:2019 - - Phase 2 trial enrollment on schedule in C3G, 24 sites recruiting - - Next-generation factor D inhibitor ACH-5228 US IND anticipated in Q4:2019 - - Reduced 2018 net cash spend to $60 million, projecting $80 million in 2019 - - Well funded with cash and securities of $271 million at December 31, 2018 - BLUE BELL, Pa., March 07, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage...

202

Earnings

-$0.18
-$0.16
-$0.14
-$0.12
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected May 1, Pre-Market

Popular Stocks

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.